The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

The drugmaker said that it would stop studying danuglipron after a participant in one of its trials experienced a possible ...

"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

The price of the vials is in line with Lilly's savings programme for Zepbound for people without insurance coverage for the drug – which is common as many policies do not cover obesity drugs ...